Business
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN,
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER\nNEW HAVEN, Conn., Sept. 26, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston, Massachusetts from October 6-9.\n\n \n \n \n \n \n \n\n \nThe presentation by Professor Alyn Morice, Head of Respiratory Medicine at HYMS and leader of the Hull Cough Clinic, will take place on October 8th and include cough data from 38 IPF patients who completed at least 1 treatment period of the CANAL trial. The presentation covers post-hoc analyses of patients' relief-of-cough duration (any ≥15-minute cough-free period), cough time (total observation time – relief time), and cough intensity (number of coughs during coughing time). The results demonstrated a significant increase in relief-of-cough time, reduced cough time, and reduced cough intensity in IPF patients with nalbuphine ER compared with placebo. The safety results of the trial were generally consistent with the known safety profile of nalbuphine ER from previous trials. The most frequently reported treatment-emergent adverse events with nalbuphine ER treatment were nausea, dizziness, anxiety, constipation, vomiting, dry mouth, headache, somnolence, dyspnea, decreased appetite, fatigue and lethargy.\nCHEST 2024October 6 – 9, 2024, Boston, MassachusettsSession: ILD Abstracts PotpourriPresentation Date & Time: October 8, 1:51 p.m. – 1:55 p.m. EDTLocation: Convention Center Exhibit Hall, Area 2BAbstract Accepted for Oral Presentation: Analysis of Relief-Of-Cough in Patients with Idiopathic Pulmonary Fibrosis Treated with Oral Nalbuphine Extended ReleasePresenter: Professor Alyn Morice is Head of Respiratory Medicine at HYMS and leader of the Hull Cough Clinic. Registration details: CHEST Annual Meeting \nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopath...